Deals
Guardant Health Decides Against Buying NeoGenomics
- Shares in Guardant had fallen nearly 20% since talks broke
- Guardant Health decided against the deal over the weekend
This article is for subscribers only.
Guardant Health Inc. has decided not to pursue a potential acquisition of rival medical testing company NeoGenomics, according to people familiar with the matter.
Guardant had hoped to use a tie up with NeoGenomics as a way to boost its reach into community cancer facilities, typically smaller, local clinics where most cancer patients are treated, the people added, asking not to be identified because the matter is private.